Protalix BioTherapeutics
PLX
$1.14
Share price
0.00%
Change (1 day)
-53.47%
Change (1 year)
Categories
Operating Margin for Protalix BioTherapeutics (PLX)
Operating Margin as of April 2024 (TTM): -71.92%
According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current Operating Margin is -71.92%. At the end of 2021 the company had an Operating Margin of -71.92%.
Operating Margin history for Protalix BioTherapeutics from 2001 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -71.92% | 593.51% |
| 2020 | -10.37% | -68.96% |
| 2019 | -33.42% | -56.75% |
| 2018 | -77.27% | -82.56% |
| 2017 | -443.18% | 39.73% |
| 2016 | -317.16% | -49.27% |
| 2015 | -625.16% | 216.52% |
| 2014 | -197.51% | -18.17% |
| 2013 | -241.38% | 615.2% |
| 2012 | -33.75% | -92.25% |
| 2011 | -435.62% | -26.13% |
| 2010 | -589.73% | -92.84% |
| 2009 | -8,239.43% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -148.12% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 14.36% | -119.97% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | -55.07% | -23.43% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -20.53% | -71.45% | 🇮🇱 Israel |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.